A Phase 3 interventional study of Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) in Acute Ischemic Stroke, Large Vessel Occlusion and Transportation of Patients, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Xuanwu Hospital, Beijing · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.
Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 24th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 17 of the 31 other live ones, and was the 48th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
By country, each count listing its studies:
Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 43 · Phase 4 5
First in 2012; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 572 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 466 across the 59 interventional studies. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 59 have an industry lead sponsor. The 10 most frequent:
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing: 30 open now, 31 under way, 2 of them phase 3. Of 14 finished, 0 (0%) have results posted.
Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 9th largest by planned enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 24 of the 30 other live ones, and was the 42nd registered.
Xuanwu Hospital, Beijing’s Ischemic Stroke studies by the year they started, since 2012.
7 of the studies testing tenecteplase in Ischemic Stroke that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07047014Phase 3Beijing Tiantan HospitalAdvancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke | 2027-03-30 |
| NCT07073469Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial | 2027-08-01 |
| NCT07201688Phase 3CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 59 studies testing tenecteplase in Ischemic Stroke, from their registry updates:
Among Xuanwu Hospital, Beijing’s 52 in Ischemic Stroke:
This tab as a report to print or save as PDF → With an account.
This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Alternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):
An Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg. Tenecteplase is for IV administration only. A single bolus dose should be administered over 5 seconds based on patient weight. Transport to ECCs or transfer physician for EVT should be initiated as early as possible after administration according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.
Drug: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Patients will receive standard treatment and be directly transferred to ECCs or transfer physician for EVT according to Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023.
Drug page: TenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tenecteplase at a nECC before EVT transfer
Level of disability (ordinal mRS score)
the ordinal score on the modified Rankin scale; The modified Rankin scale is a measure of disability, with scores ranging from 0 (no symptoms) to 6 (death).
Time frame: at 90 (±7) days
Excellent outcome
mRS of 0-1 vs. 2-6
Time frame: at 90 (±7) days
Functional independence
mRS of 0-2 vs. 3-6
Time frame: at 90 (±7) days
Ambulatory and self-care capable
mRS of 0-3 vs. 4-6
Time frame: at 90 (±7) days
Health-related quality of life
Score on the EuroQol Group 5-Dimension 5-Level \[EQ-5D-5L\] questionnaire; range, -0.39 to 1, with higher scores indicating better quality of life)
Time frame: at 90 (±7) days
Incidence of arterial recanalization
Arterial imaging performed at ECC arrival, either CTA/MRA/or first run of DSA
Time frame: Day 1
First pass reperfusion
First pass reperfusion refers to achievement of recanalization by single pass, near-complete to complete recanalization of the occlusion site (eTICI 2c or 3) and no need for rescue treatment
Time frame: intraoperative, immediately after the first pass
Successful reperfusion
successful reperfusion is defined as extended Treatment In Cerebral Ischemia (eTICI) grades of 2b, 2c or 3
Time frame: immediately after the endovascular intervention
Recanalization
Time frame: at 24 (±12) hours
Symptomatic intracranial hemorrhage (sICH)
using Heidelberg criteria
Time frame: within 36 hours
Parenchymal hematoma type 2 (PH2)
Time frame: within 36 hours
All-cause mortality
Time frame: up to 90 (±7) days
Plan to share: No — According to Chinese laws and regulations, the IPD will not be shared.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 26 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase